港股異動 | 旭輝控股集團(0884.HK)漲近6% 今年前2月銷售回款達269億元 與去年同期持平
格隆匯3月3日丨旭輝控股集團(0884.HK)漲近6%,報5.41港元,總市值475億港元。旭輝控股集團昨日宣佈,公司2022年1-2月已達成269億元的銷售回款,與去年同期持平。在行業流動性危機下,今年以來,旭輝卻好消息頻傳。1月10日,旭輝完成額外增發的1.5億美元綠色優先票據,展現其在綠色金融上的行業領先性。 2月11日,旭輝收到了中國銀行間市場交易商協會的50億中期票據的接受註冊通知書。這是旭輝首次獲得交易商協會MTN品種的註冊。2022年前兩月269億元的銷售回款再次顯示了旭輝健康的現金流,確保了其優異的償債能力。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.